Corcept Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
FY Revenue (est.)
$1.1Bnext fiscal year
Monitoring Framework
Key Performance Indicators
Quarterly Product Revenue Quarterly164.9MTarget: 950000000 to 1050000000 (Full-Year 2026 Guidance)
Cash and Investments Balance Quarterly515.4M
Watch Items
- Lifyorli (relacorilant) commercial launch trajectory in platinum-resistant ovarian cancerTrigger: Initial prescription volume and market uptake in Q2 and Q3 2026Action: Monitor quarterly product revenue growth and launch-related SG&A expenses
- European Medicines Agency (EMA) regulatory decision on relacorilant MAA for ovarian cancerTrigger: Regulatory decision expected by year-end 2026Action: Track regulatory updates and prepare European commercial launch infrastructure
- Phase 2b MONARCH trial data readout for miricorilant in MASHTrigger: Clinical trial results expected by the end of 2026Action: Evaluate efficacy and safety data to determine Phase 3 development path
- New Drug Application (NDA) resubmission for relacorilant in hypercortisolismTrigger: Resubmission announced on June 17, 2026Action: Monitor FDA acceptance of the filing and subsequent PDUFA action date
Research as of 2 Sep 2026